P8IP
FATE icon

Pier 88 Investment Partners’s Fate Therapeutics FATE Stock Holding History

Pier 88 Investment Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,885
Closed -$637K – 91
2021
Q4 		$637K Buy
10,885
+8,820
+427% +$500K 0.14% 82
2021
Q3 		$122K Sell
2,065
-7,727
-79% -$606K 0.04% 110
2021
Q2 		$850K Buy
9,792
+3,000
+44% +$242K 0.24% 85
2021
Q1 		$560K Sell
6,792
-560
-8% -$53.7K 0.19% 88
2020
Q4 		$669K Sell
7,352
-23,965
-77% -$1.49M 0.22% 91
2020
Q3 		$1.25M Buy
31,317
+7,225
+30% +$252K 0.38% 54
2020
Q2 		$827K Buy
+24,092
New +$718K 0.24% 84

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Pier 88 Investment Partners's FATE Position: Q1 2022 in Review

Pier 88 Investment Partners sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 10,885 shares — an estimated $637K sold.

Pier 88 Investment Partners first reported a position in FATE in Q2 2020 and held it in 7 quarters. The position peaked at $1.25M in Q3 2020. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Pier 88 Investment Partners reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Pier 88 Investment Partners sold 10,885 Fate Therapeutics shares in Q1 2022, an estimated $637K.
  • Pier 88 Investment Partners first reported a position in Fate Therapeutics in Q2 2020 and held it in 7 quarters.
  • Pier 88 Investment Partners's Fate Therapeutics position peaked at $1.25M in Q3 2020.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Pier 88 Investment Partners's 13F filing for Q1 2022, filed 13 May 2022.